Islet transplant trial aims to free type 1 patients from severe lows
NCT ID NCT00679042
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests whether transplanting insulin-making cells (islets) from donors can improve blood sugar control in people with type 1 diabetes who still have dangerous low blood sugar episodes despite intensive insulin therapy. About 21 participants receive the transplant along with lifelong anti-rejection drugs. The main goal is to see if one year after the transplant, patients have a normal blood sugar marker (HbA1c ≤ 6.5%) and no severe hypoglycemic events.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Illinois at Chicago Medical Center
Chicago, Illinois, 60612, United States